Gain Therapeutics (GANX) awards director 25,000 stock options

Rhea-AI Filing Summary

Gain Therapeutics director Claude Nicaise received a grant of stock options covering 25,000 shares of common stock at an exercise price of $1.68 per share. The options expire on July 15, 2036 and vest in 12 equal monthly installments starting July 24, 2026, subject to his continuous service, resulting in 25,000 options held directly after the grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nicaise Claude

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 25,000 options Exercise price: $1.68 per share Underlying shares: 25,000 shares +3 more

6 metrics

Stock options granted 25,000 options Grant to director Claude Nicaise on 2026-07-15

Exercise price $1.68 per share Conversion or exercise price of the options

Underlying shares 25,000 shares Common stock underlying the stock option award

Expiration date 2036-07-15 Options expire on this date

Vesting period 12 months Vests in 12 equal monthly installments from July 24, 2026

Post-grant derivative holdings 25,000 options Total derivative securities held directly after the grant

Key Terms

Stock Option (right to buy), vests, continuous service

3 terms

Stock Option (right to buy) financial

"Security title reported as "Stock Option (right to buy)""

vests financial

"The option vests in 12 equal monthly installments"

continuous service financial

"subject to the Reporting Person's continuous service through the applicable vesting date"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 08:33 AM Accepted by SEC EDGAR 07/17/2026 - 08:32 AM Learn about SEC filing dates

FAQ

What insider transaction did Gain Therapeutics (GANX) report for Claude Nicaise?

Claude Nicaise received a grant of stock options for 25,000 shares of Gain Therapeutics common stock. The options carry an exercise price of $1.68 per share and expire on July 15, 2036, representing a compensation-related acquisition, not an open-market trade.

How many Gain Therapeutics (GANX) shares are covered by Claude Nicaise’s new options?

The option award covers 25,000 shares of Gain Therapeutics common stock. These are derivative securities, giving Nicaise the right to buy that many shares if exercised, subject to vesting and the $1.68 per share exercise price disclosed in the report.

What is the exercise price and expiration date of Claude Nicaise’s GANX stock options?

The options have an exercise price of $1.68 per share and an expiration date of July 15, 2036. This defines the cost to acquire each share under the grant and the final date by which the options must be exercised, assuming they have vested.

How do the vesting terms work for Claude Nicaise’s Gain Therapeutics (GANX) stock options?

The option vests in 12 equal monthly installments beginning on July 24, 2026. Each month, a portion becomes exercisable, and vesting is conditioned on Nicaise’s continuous service with the company through each applicable vesting date, as described in the footnote.

Did the Gain Therapeutics (GANX) Form 4 report any stock sales by Claude Nicaise?

No. The Form 4 reports only an acquisition of stock options coded as a grant (transaction code A). There are no sales or dispositions of Gain Therapeutics common stock or options disclosed in this particular filing for Claude Nicaise.

What is Claude Nicaise’s derivative holdings in GANX after this option grant?

Following the transaction, Claude Nicaise directly holds 25,000 stock options as reported. These options are derivative securities tied to an equal number of Gain Therapeutics common shares, subject to their stated vesting schedule, exercise price, and 2036 expiration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nicaise Claude

(Last) (First) (Middle)

C/O GAIN THERAPEUTICS, INC.

4800 MONTGOMERY LANE, SUITE 220

(Street)

BETHESDA MARYLAND 20814

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gain Therapeutics, Inc. [ GANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.68	07/15/2026		A		25,000		(1)	07/15/2036	Common Stock	25,000	$0.00	25,000	D

Explanation of Responses:

1. The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.

	/s/ Claude Nicaise	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)